Ind-Swift Laboratories Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹169.79 crore, reflecting a quarter-on-quarter *(QoQ) increase of 12.56 per cent from ₹150.85 crore. This corresponds to a year-on-year *(YoY) growth of 22.82 per cent.
Operating Profit
Operating Profit stands at ₹15.42 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1,017.86 per cent from ₹-1.68 crore. This corresponds to a year-on-year *(YoY) growth of 267.79 per cent.
PBDT
PBDT stands at ₹20.08 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 20.48 per cent from ₹25.25 crore. This corresponds to a year-on-year *(YoY) decline of 91.56 per cent.
Profit Before Tax
Profit Before Tax stands at ₹11.96 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 27.12 per cent from ₹16.41 crore. This corresponds to a year-on-year *(YoY) decline of 94.81 per cent.
Net Profit
Net Profit stands at ₹15.11 crore, reflecting a quarter-on-quarter *(QoQ) increase of 58.39 per cent from ₹9.54 crore. This represents a 93.20 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Ind-Swift Laboratories Ltd Earnings
- YOY
- QOQ
Ind-Swift Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Ind-Swift Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Ind-Swift Laboratories Ltd Financial Reports
Ind-Swift Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Ind-Swift Labs. | 4.21% | 8.75% | 38.77% | 56.38% | 147.24% | 92.32% |
| Indoco Remedies | 2.77% | 1.99% | 20.75% | 23.79% | 13.46% | -25.72% |
| Venus Remedies | -3.20% | -4.22% | 5.54% | 73.30% | 132.65% | 260.71% |
| NGL Fine Chem | 4.10% | 9.47% | 14.19% | 35.61% | 124.76% | 153.20% |
| Hester Bios | -6.12% | -4.52% | 6.35% | 46.70% | 33.55% | 14.49% |
| Windlas Biotech | -0.73% | -1.83% | 1.17% | 5.53% | 12.56% | -8.61% |
| Titan Biotech | 0.57% | 7.66% | -8.09% | -12.16% | 97.38% | 337.84% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : N R Munjal
ED / Joint MD / Promoter : Himanshu Jain
Executive Director : Rishav Mehta
Executive Director : Sahil Munjal
Independent Non Executive Women Director : Neerja Chathley
Independent Non Exe. Director : Rajinder Kumar Gupta
Independent Non Exe. Director : SUBODH GUPTA
Independent Non Exe. Director : Prabhat Khurana
VP / Company Secretary / Compliance Officer : Pradeep Verma